Parabilis surpassed Kailera Therapeutics’ recent record for the largest biotech initial public offering with a $670 million debut on Nasdaq, generating significant attention in the biotechnology and pharmaceutical sectors as of June 11. Experts say that while these IPOs signal renewed investor appetite, such large offerings may remain limited to companies with advanced clinical pipelines.
“These transactions are getting completed. It’s a really big change from the environment just a year ago, or two years ago, where you basically couldn’t give biotech new issues away,” said Les Funtleyer, healthcare portfolio manager at E Squared. He attributed some of the current excitement to broader market trends fueled by high-profile artificial intelligence IPOs like Open AI and Anthropic, but noted that biotech activity is still modest compared to those technology debuts.
Peptide-maker Parabilis achieved an enterprise value of $2.65 billion after its IPO and had previously raised $800 million in private rounds. According to George Thampy, a biotech IPO advisor, “there was a torrent of new demand after the public flip, and that the order book was significantly more oversubscribed.” Thampy also highlighted Parabilis’ leadership team and partnerships as factors driving investor interest.
Kailera’s final total after underwriters’ options reached $718.8 million. Chief Commercial Officer Jamie Coleman said that strong interest during their roadshow reflected confidence in Kailera’s late-stage obesity pipeline already partly derisked with data from China. Pitchbook Senior Analyst Ben Zercher contrasted Parabilis’ longer path—including rebranding from FogPharma and securing regulatory designations for its lead cancer asset—with Kailera’s rapid fundraising since forming in 2024.
Both Funtleyer and Zercher emphasized that these outsized raises are likely reserved for biotechs with proven assets rather than preclinical programs: “If you start to see preclinical companies coming public with multi-billion dollar valuations, I think that’s when you start to look at the panic button—but there’s no indication that that’s the case now,” Funtleyer said.
The ongoing wave includes other companies like Kardigan seeking more moderate raises while maintaining focus on advanced clinical results. Zercher said, “With the biotech window reopened, the volume of IPOs reflects a backlog of quality companies... rather than a wave of hype.” As newly listed firms work to sustain momentum—Parabilis shares closed up 58% on opening day while Kailera fell 24% since debut—market observers continue watching whether this trend will persist or cool.
